Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$55.45 USD

55.45
10,808,187

+1.13 (2.08%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $55.46 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations

by Zacks Equity Research

Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.

Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bristol Myers Squibb (BMY) Stock Moves -0.21%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $70.62 in the latest trading session, marking a -0.21% move from the prior day.

Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Merck (MRK) Posts Positive Results From PAH Drug Study

by Zacks Equity Research

Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $68.48, moving -1.75% from the previous trading session.

Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock

by Zacks Equity Research

Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $70.24 in the latest trading session, marking a -1.69% move from the prior day.

Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More

by Zacks Equity Research

Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.

Is Exelixis' (EXEL) Growth Story Likely to Continue?

by Zacks Equity Research

Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.

Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy

by Zacks Equity Research

Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.

Shaun Pruitt headshot

Should Investors Buy Bristol Myers Squibb Stock?

by Shaun Pruitt

BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.

Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?

by Zacks Equity Research

Bristol Myers (BMY) expects recent drug approvals to generate an incremental stream of revenues and combat competition for its key drugs.

Bristol Myers Squibb (BMY) Stock Moves -0.86%: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.09, marking a -0.86% move from the previous day.

Bristol Myers Squibb (BMY) Stock Moves -0.49%: What You Should Know

by Zacks Equity Research

In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.71, marking a -0.49% move from the previous day.

Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?

by Zacks Equity Research

Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Bristol Myers Squibb (BMY) Stock Moves -0.81%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed the most recent trading day at $70.71, moving -0.81% from the previous trading session.

Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

by Zacks Equity Research

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib

by Zacks Equity Research

Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.

Bristol Myers (BMY) Skin Cancer Drug Gets EC's Approval

by Zacks Equity Research

Bristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.

Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for PWV

Bristol Myers Squibb (BMY) Stock Moves -0.36%: What You Should Know

by Zacks Equity Research

Bristol Myers Squibb (BMY) closed at $71.52 in the latest trading session, marking a -0.36% move from the prior day.